Management ChangeJun 30, 2026, 04:13 PM
Sera Prognostics Appoints Mark Capone to Board of Directors
AI Summary
Sera Prognostics, Inc. announced the appointment of Mark Capone to its Board of Directors, effective July 1, 2026. Mr. Capone will also serve on the Compensation Committee. He brings over 40 years of experience in the healthcare sector, including a significant tenure as CEO of Myriad Genetics, where he transformed the company into a precision medicine leader. His compensation includes an initial equity award of $167,072 and annual equity awards of $88,359.
Key Highlights
- Mark Capone appointed to Sera Prognostics' Board of Directors, effective July 1, 2026.
- Mr. Capone also appointed to the Compensation Committee of the Board.
- His initial term as a Class II director expires at the 2029 annual meeting.
- Will receive an initial equity award with a grant date fair value of $167,072 (or 150,000 option equivalents).
- Entitled to annual equity awards of $88,359 (or 75,000 option equivalents) after each annual meeting.
- Mr. Capone brings over 40 years of experience, including as former CEO of Myriad Genetics.
Price Impact
More from SERA